N/A N=128 Randomized Supportive Care

Rivanna Ultrasound for Neuraxial Block

Analgesia

Bottom Line

View on ClinicalTrials.gov: NCT03214640 ↗

Enrolled (actual)

128

Serious AEs

0.0%

Results posted

Jul 2021

Primary outcome: Primary: Time to Success of Neuraxial Block Placement — 122; 111; 50; 78.5 seconds

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Rivanna Accuro US Device (Device); Palpation (Other); Neuraxial Analgesia (Procedure); Spinal Block (Procedure)
Age: Adult · 18+ yrs
Sex: Female
Sponsor: Wake Forest University Health Sciences
Primary completion: Apr 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Time to Success of Neuraxial Block Placement	122; 111; 50; 78.5	—
SECONDARY Total Number of Needle Passes Per Placement	2; 1; 1; 1	—
SECONDARY Needle Passing Success at First Attempt	10; 18; 18; 24	—

Summary

We hypothesize that the Rivanna Accuro or similar U/S device would reduce time to success of identifying epidural and/or intrathecal spaces as compared to conventional palpation method.

Eligibility Criteria

Inclusion Criteria

BMI >30
Female requesting analgesia for delivery, be it via vaginal or cesarean delivery

Exclusion Criteria

Allergy to ultrasound gel
Contraindication to receiving neuraxial analgesia
Under the age of 18

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03214640). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.